Skip to main content
Clinical Trials/NL-OMON38713
NL-OMON38713
Completed
Phase 4

Influence of exceptional patient characteristics on everolimus exposure - INPRES

niversitair Medisch Centrum Sint Radboud0 sites75 target enrollmentTBD

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Breast cancer
Sponsor
niversitair Medisch Centrum Sint Radboud
Enrollment
75
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional

Investigators

Sponsor
niversitair Medisch Centrum Sint Radboud

Eligibility Criteria

Inclusion Criteria

  • \- Adult women (\* 18 years of age) with metastatic or locally advanced breast cancer not
  • amenable to curative treatment by surgery or radiotherapy.
  • \- Histological or cytological confirmation of estrogen\-receptor positive (ER\+) breast cancer
  • \- Postmenopausal women
  • \- Progression following a non\-steroidal aromatase inhibitor
  • \- Radiological or clinical evidence of recurrence or progression on last systemic therapy prior to enrollment.
  • \- Falling into one of the following categories:
  • o elderly patients (age \* 70 years and BMI \< 30 kg/m2\); or
  • o obese patients (BMI \* 30 kg/m2 and age \< 70 years); or
  • o control patients (BMI \< 30 kg/m2 and age \< 70 years);

Exclusion Criteria

  • \- Patients aged \* 70 years AND BMI \* 30 kg/m2
  • \- HER2\-overexpressing patients by local laboratory testing (IHC 3\+ staining or in situ hybridization positive)
  • \- Previous treatment with exemestane or mTOR inhibitors. Except for the treatment with exemestane in the adjuvant setting
  • \- Known hypersensitivity to mTOR inhibitors, e.g. sirolimus (rapamycin)
  • \- Patients with a known history of HIV seropositivity
  • \- Any severe and / or uncontrolled medical condition such as:
  • o Unstable angina pectoris, serious uncontrolled cardiac arrhythmia
  • o Patients with severe hepatic impairment (Child\-Pugh A/B/C)
  • o Uncontrolled diabetes mellitus
  • o Impairment of gastrointestinal function or gastrointestinal disease that may

Outcomes

Primary Outcomes

Not specified

Similar Trials